share_log

华润双鹤(600062.SH):子公司通过GMP符合性检查

China Resources Double-Crane Pharmaceutical (600062.SH): Subsidiary passes GMP compliance inspection.

Gelonghui Finance ·  Aug 6 04:56

On August 6th, Gelonghui reported that China Resources Double-Crane Pharmaceutical (stock code 600062.SH) announced that its subsidiary Zhejiang Xinsaike Pharmaceutical Co., Ltd. received a notice of GMP compliance inspection results from the Zhejiang Provincial Drug Administration website. In this drug GMP compliance inspection, the first-time pre-market GMP compliance inspection of Dapoxetine Hydrochloride was added to the existing product production line. The total investment in the new production equipment and facilities in the workshop is 1.163 million yuan (unaudited); the first time that the GMP compliance inspection of Trimethoprim Hydrochloride was passed after the new production line was established, and the total investment in the new production equipment and facilities in the workshop was 1.5569 million yuan (unaudited).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment